Tenvie Therapeutics

Executive Summary

Tenvie Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel small molecule therapies targeting neurological, cardiometabolic, and ophthalmic diseases. By focusing on fundamental disease drivers such as inflammation, metabolic dysfunction, and impaired lysosomal function, Tenvie aims to address significant unmet medical needs and improve patient outcomes. Although the company remains in early stages with no publicly disclosed pipeline candidates, its scientific approach leverages validated biology and established drug modalities. The management team and scientific founders bring deep expertise in CNS and metabolic disorders, positioning Tenvie to advance multiple programs toward clinical development. Given its recent inception and the competitive landscape, the company's progress will depend on successful preclinical validation and securing additional financing.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing or Phase 1 Initiation40% success
• Q2 2027Preclinical Proof-of-Concept Data for Metabolic Program30% success
• Q3 2026Series A or Seed Extension Financing50% success